MedTrace Logo

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

NCT00025532 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-09-14

No results posted yet for this study

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer.

PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have gastrointestinal cancer.

Conditions

Interventions

OTHER

iodine I 131 monoclonal antibody CC49-deltaCH2

Sponsors & Collaborators

Principal Investigators

  • Margaret A. Tempero, MD · University of California, San Francisco

Study Design

Purpose
TREATMENT

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00025532 on ClinicalTrials.gov